Lorraine McCarra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lorraine McCarra has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anna Keogh
Department of Histopathology, St. James’s Hospital, Dublin, Ireland
1 shared publication - Chris Maria Jose
School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland
1 shared publication - Ciara Murphy
Department of Histopathology, Labmed Directorate, St. James’s Hospital, D08 NHY1 Dublin, Ireland
1 shared publication - Gerard J. Fitzmaurice
Surgery, Anaesthesia and Critical Care Directorate, St James’s Hospital, D08 NHY1 Dublin, Ireland
1 shared publication - Glòria Gornés Pons
Thoracic Oncology Research Group, Central Pathology Laboratory, Trinity St. James’s Cancer Institute (TSJCI), St. James’s Hospital, D08 RX0X Dublin, Ireland
1 shared publication - Lisa Ryan
Department of Histopathology, Labmed Directorate, St. James’s Hospital, D08 NHY1 Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 19 September 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (9) , 2576
An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC)
The JADE family comprises three members encoded by individual genes and roles for these proteins have been identified in chromatin remodeling, cell cycle progression, cell regeneration and the DNA damage response. JADE family members, and in particular JADE2 have not been studied in any great detail in cancer. Using a series of standard biological and bioinformatics approaches we investigated JADE2 expression in surgically resected non-small cell lung cancer (NSCLC) for both mRNA and protein to examine for correlations between JADE2 expression and overall survival. Additional correlations were identified using bioinformatic analyses on multiple online datasets. Our analysis demonstrates that JADE2 expression is significantly altered in NSCLC. High expression of JADE2 is associated with a better 5-year overall survival. Links between JADE2 mRNA expression and a number of mutated genes were identified, and associations between JADE2 expression and tumor mutational burden and immune cell infiltration were explored. Potential new drugs that can target JADE2 were identified. The results of this biomarker-driven study suggest that JADE2 may have potential clinical utility in the diagnosis, prognosis and stratification of patients into various therapeutically targetable options.
- 19 September 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (9) , 2576
Open AccessAn Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC)
The JADE family comprises three members encoded by individual genes and roles for these proteins have been identified in chromatin remodeling, cell cycle progression, cell regeneration and the DNA damage response. JADE family members, and in particular JADE2 have not been studied in any great detail in cancer. Using a series of standard biological and bioinformatics approaches we investigated JADE2 expression in surgically resected non-small cell lung cancer (NSCLC) for both mRNA and protein to examine for correlations between JADE2 expression and overall survival. Additional correlations were identified using bioinformatic analyses on multiple online datasets. Our analysis demonstrates that JADE2 expression is significantly altered in NSCLC. High expression of JADE2 is associated with a better 5-year overall survival. Links between JADE2 mRNA expression and a number of mutated genes were identified, and associations between JADE2 expression and tumor mutational burden and immune cell infiltration were explored. Potential new drugs that can target JADE2 were identified. The results of this biomarker-driven study suggest that JADE2 may have potential clinical utility in the diagnosis, prognosis and stratification of patients into various therapeutically targetable options.